• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

导管原位癌(DCIS)中浸润淋巴细胞的评估——三种不同方法学的评估及与 Oncotype DX DCIS 评分的相关性。

Tumour-infiltrating lymphocytes in ductal carcinoma in situ (DCIS)-assessment with three different methodologies and correlation with Oncotype DX DCIS Score.

机构信息

Department of Pathology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.

Department of Pathology, Cleveland Clinic, Cleveland, OH, USA.

出版信息

Histopathology. 2020 Nov;77(5):749-759. doi: 10.1111/his.14181. Epub 2020 Sep 26.

DOI:10.1111/his.14181
PMID:32557780
Abstract

AIMS

Tumour-infiltrating lymphocytes (TILs) are prognostic in invasive breast cancer; however, their prognostic significance in ductal carcinoma in situ (DCIS) has not been established. The Oncotype DX (ODX) Breast DCIS Score test is a genomic assay used to predict the local recurrence risk. The aims of this study were to quantify TILs in DCIS by the use of three methodologies, and correlate them with the ODX DCIS Score.

METHODS AND RESULTS

We studied 97 DCIS cases, all with an ODX DCIS Score. Cases with a low ODX DCIS Score were considered as one group, and those with an intermediate/high ODX Score were considered together. TILs were quantified on haematoxylin and eosin-stained slides. The methodologies used to quantify TILS included assessment of stromal TILs, assessment of touching TILs, and assessment of circumferential TILS. In cases with >5% stromal TILS, the percentage of stromal TILS was considered to be high. In cases with a mean number of more than five touching TILs per DCIS duct, TILs were considered to be present. The ODX DCIS Score was intermediate/high in 27 (28%) cases and low in 70 (72%) cases. There were >5% stromal TILs in 33 (34%) cases, and more than five touching TILs per DCIS duct in 15 (15%) cases; circumferential TILs were present in nine (9%) cases. In univariate analysis, a low ODX DCIS Score showed significant associations with absent touching TILS (P = 0.027), stromal TILs < 5% (P = 0.031), and absent circumferential TILs (P = 0.002). In logistic regression analysis adjusted for necrosis and nuclear grade, touching TILs and circumferential TILs showed significant associations with the ODX DCIS Score, whereas stromal TILs did not.

CONCLUSIONS

Our results suggest that both the presence of TILs and the spatial arrangement of TILs or close proximity of TILs to DCIS, and TILs touching or encircling DCIS, may be predictive of recurrence.

摘要

目的

肿瘤浸润淋巴细胞(TILs)在浸润性乳腺癌中具有预后意义;然而,其在导管原位癌(DCIS)中的预后意义尚未确定。Oncotype DX(ODX)乳腺 DCIS 评分检测是一种用于预测局部复发风险的基因组检测。本研究的目的是使用三种方法学来量化 DCIS 中的 TILs,并将其与 ODX DCIS 评分相关联。

方法和结果

我们研究了 97 例 DCIS 病例,所有病例均进行了 ODX DCIS 评分。低 ODX DCIS 评分的病例被视为一组,而中间/高 ODX 评分的病例被视为一组。TILs 在苏木精和伊红染色切片上进行量化。用于量化 TILS 的方法包括评估间质 TILs、评估触碰到的 TILs 和评估环绕 TILs。在间质 TILS 百分比大于 5%的病例中,认为间质 TILS 百分比高。在每个 DCIS 导管中平均有超过 5 个触碰到的 TIL 的情况下,认为存在 TILs。27 例(28%)病例的 ODX DCIS 评分中等/高,70 例(72%)病例的 ODX DCIS 评分低。33 例(34%)病例的间质 TILS 百分比大于 5%,15 例(15%)病例的每个 DCIS 导管中触碰到的 TILs 多于 5 个,9 例(9%)病例存在环绕 TILs。在单因素分析中,低 ODX DCIS 评分与触碰到的 TILs 缺失显著相关(P=0.027),间质 TILs<5%(P=0.031)和不存在环绕 TILs(P=0.002)显著相关。在调整了坏死和核分级的逻辑回归分析中,触碰到的 TILs 和环绕 TILs与 ODX DCIS 评分显著相关,而间质 TILs 则不然。

结论

我们的研究结果表明,TILs 的存在以及 TILs 的空间排列或 TILs 与 DCIS 的接近程度,以及 TILs 触碰到或环绕 DCIS,可能与复发相关。

相似文献

1
Tumour-infiltrating lymphocytes in ductal carcinoma in situ (DCIS)-assessment with three different methodologies and correlation with Oncotype DX DCIS Score.导管原位癌(DCIS)中浸润淋巴细胞的评估——三种不同方法学的评估及与 Oncotype DX DCIS 评分的相关性。
Histopathology. 2020 Nov;77(5):749-759. doi: 10.1111/his.14181. Epub 2020 Sep 26.
2
Touching tumour-infiltrating lymphocytes in low-risk ductal carcinoma in situ (DCIS) correlate with upgrading to high-grade DCIS.低危型乳腺导管原位癌(DCIS)中浸润淋巴细胞的检出与向高级别 DCIS 升级相关。
Histopathology. 2022 Jan;80(2):291-303. doi: 10.1111/his.14539. Epub 2021 Sep 22.
3
Prognostic significance of tumor-infiltrating lymphocytes in ductal carcinoma in situ of the breast.肿瘤浸润淋巴细胞对乳腺导管原位癌的预后意义。
Mod Pathol. 2018 Aug;31(8):1226-1236. doi: 10.1038/s41379-018-0040-8. Epub 2018 Mar 20.
4
The prognostic significance of immune microenvironment in breast ductal carcinoma in situ.乳腺导管原位癌中免疫微环境的预后意义。
Br J Cancer. 2020 May;122(10):1496-1506. doi: 10.1038/s41416-020-0797-7. Epub 2020 Mar 17.
5
The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast.乳腺导管原位癌中肿瘤浸润淋巴细胞(TILs)的流行率和临床相关性。
Ann Oncol. 2017 Feb 1;28(2):321-328. doi: 10.1093/annonc/mdw623.
6
Tumor-Infiltrating Lymphocytes in a Contemporary Cohort of Women with Ductal Carcinoma In Situ (DCIS).肿瘤浸润淋巴细胞在当代女性导管原位癌(DCIS)队列中的作用。
Ann Surg Oncol. 2019 Oct;26(10):3337-3343. doi: 10.1245/s10434-019-07562-x. Epub 2019 Jun 25.
7
Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situ.肿瘤浸润淋巴细胞分析揭示了原位乳腺导管癌的两个新的生物学不同亚群。
BMC Cancer. 2018 Feb 3;18(1):129. doi: 10.1186/s12885-018-4013-6.
8
Quantitative nuclear histomorphometric features are predictive of Oncotype DX risk categories in ductal carcinoma in situ: preliminary findings.定量核组织形态计量学特征可预测导管原位癌的 Oncotype DX 风险类别:初步研究结果。
Breast Cancer Res. 2019 Oct 17;21(1):114. doi: 10.1186/s13058-019-1200-6.
9
Evaluation of tumor infiltrating lymphocytes as a prognostic biomarker in patients with ductal carcinoma in situ of the breast.评估肿瘤浸润淋巴细胞作为乳腺导管原位癌患者的预后生物标志物。
Breast Cancer Res Treat. 2024 Nov;208(1):9-18. doi: 10.1007/s10549-024-07466-9. Epub 2024 Aug 24.
10
Will oncotype DX DCIS testing guide therapy? A single-institution correlation of oncotype DX DCIS results with histopathologic findings and clinical management decisions.Oncotype DX DCIS 检测能否指导治疗?单机构的 Oncotype DX DCIS 检测结果与组织病理学发现和临床管理决策的相关性。
Mod Pathol. 2018 Apr;31(4):562-568. doi: 10.1038/modpathol.2017.172. Epub 2017 Dec 15.

引用本文的文献

1
Decoding tumor-infiltrating lymphocytes heterogeneity in ductal carcinoma in situ: immune microenvironment dynamics and prognostic insights.解码导管原位癌中肿瘤浸润淋巴细胞的异质性:免疫微环境动态及预后见解
Discov Oncol. 2025 Jul 28;16(1):1435. doi: 10.1007/s12672-025-03288-3.
2
Predicting Breast Cancer Events in Ductal Carcinoma In Situ (DCIS) Using Generative Adversarial Network Augmented Deep Learning Model.使用生成对抗网络增强深度学习模型预测导管原位癌(DCIS)中的乳腺癌事件
Cancers (Basel). 2023 Mar 23;15(7):1922. doi: 10.3390/cancers15071922.
3
Tumor Infiltrating Lymphocytes in Multi-National Cohorts of Ductal Carcinoma In Situ (DCIS) of Breast.
多国原位导管癌(DCIS)队列中的肿瘤浸润淋巴细胞。
Cancers (Basel). 2022 Aug 13;14(16):3916. doi: 10.3390/cancers14163916.
4
Tumour-infiltrating lymphocytes in oropharyngeal cancer: a validation study according to the criteria of the International Immuno-Oncology Biomarker Working Group.口咽癌中的肿瘤浸润淋巴细胞:根据国际免疫肿瘤生物标志物工作组标准的验证研究。
Br J Cancer. 2022 Jun;126(11):1589-1594. doi: 10.1038/s41416-022-01708-7. Epub 2022 Jan 18.
5
Prognostic and predictive significance of tumor infiltrating lymphocytes for ductal carcinoma in situ.肿瘤浸润淋巴细胞对导管原位癌的预后及预测意义
Oncoimmunology. 2021 Mar 18;10(1):1875637. doi: 10.1080/2162402X.2021.1875637.